The market for pharmaceuticals used to treat brain tumours is known as the ” Brain Tumor Drugs Market,” and it is a subset of the pharmaceutical business. Brain tumours are abnormal cell growths in the brain that may or may not be cancerous (benign) or malignant (cancerous). They can have a variety of symptoms and be fatal.
In recent years, there have been substantial developments and breakthroughs in the field of brain tumour medications, with the goal of enhancing patient outcomes and extending survival times. Chemotherapy, radiation therapy, and surgery are frequently used to treat brain tumours. Drug therapy, however, are essential for controlling brain tumours, especially for those that cannot be surgically removed or in situations where tumours recur.
Get Recently Updated Report of Market as Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16725
The market for drugs to treat brain tumours is projected to expand at a 9.2% CAGR from 2023 to 2033. In 2023 and 2033, respectively, the market value is projected to reach US$ 2.65 billion and US$ 6.30 billion. Utilising nanoparticles, drugs are delivered in combination directly to cancer cells or tumours. Additionally, this technique has led to a decrease in medication dosage, an extension of the shelf life, and a decrease in toxicity. The blood-brain barrier, which has been a significant barrier in the treatment of brain tumours, has been proved to be successfully crossed by a small number of nanodrugs.
A brain tumour is an abnormal mass of tissue in which the growth and division of brain cells occurs rapidly and uncontrollably. Primary brain tumours and metastatic brain tumours are the two categories into which brain cancers are divided. Primary brain tumours are those that develop from the tissues of the brain or the tissues around the brain. Pharmaceutical companies have improved supply chain management, which has led to more investment in R&D, manufacturing quality assurance, and research and development.
Key Takeaways:
- The brain tumor drugs market is expected to record a CAGR of 9.2% during the forecast period 2023 to 2033.
- The primary drivers of the market are an increase in brain cancer prevalence, the presence of promising pipeline candidates, and an increased need for precision and customized treatment to drive market expansion.
- North America dominated the brain tumor drugs market.
In case of any queries, don’t hesitate to contact our analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16725
Key Development in the Brain Tumor Drugs Market:
- April 2021 – MindMed and Nextage Therapeutics signed a Memorandum of Understanding (MOU) to maximize the administration of selected psychedelic drug candidates using Nextage’s unique Brain Targeting Liposome System (BTLS) delivery technology.
- March 2021 – Roche and GenMark Diagnostics signed a comprehensive merger agreement for Roche to entirely acquire GenMark for US$ 24.05 per share in an all-cash transaction.
- September 2022 – F. Hoffmann-La Roche Ltd. announced an agreement to acquire Good Therapeutics. With this acquisition, the firm gains access to Good Therapeutic’s platform technology, which is relevant to a wide range of sectors such as cancer, autoimmune illnesses, metabolic disease, and pain management.
- June 2022 – Novartis AG received the United States FDA approval for Tafinlar + Mekinist for the treatment of paediatric and adult patients with solid cancers containing the BRAF V600E mutation. BRAF mutations are responsible for tumor growth in over 20 different tumor types, including brain, thyroid, and others.
- November 2021 – Pfizer Inc. purchased Trillium Therapeutics, a clinical-stage immuno-oncology startup focused on creating novel cancer medicines.
Customize Your Report: Tailor the Exclusive Insights to Your Brain Tumour Drug Market Strategy @ https://www.futuremarketinsights.com/customization-available/rep-gb-16725
Competitive Landscape:
Prominent Participants in the Market
- AstraZeneca plc
- Johnson & Johnson Inc
- Merck & Co
- Pfizer Inc
- Hoffmann-La Roche Ltd
- Y-mAbs Therapeutics, Inc
- Shimadzu Corporation
- Bristol-Myers Squibb
- Bayer AG
- Reddy’s Laboratories Ltd
- Among others
Key Segment
By Therapy:
- Targeted Therapy
- Chemotherapy
- Immunotherapy
- Others
By Indication:
- Pituitary
- Meningioma
- Glioma
- Others
By Distribution Channel:
- Hospital Pharmacy
- Retail & Online Pharmacy
Gain Immediate Access to Detailed Market Insights: Purchase Now @ https://www.futuremarketinsights.com/checkout/16725
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- The Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
